A new initiative launched 29 September 2000 encourages private-sector involvement in attacking several of the world's most deadly infectious diseases. Through its new Challenge Grants program, the National Institute of Allergy and Infectious Diseases (NIAID) provides matching funds to companies who will commit their own dollars and resources toward developing new drugs and vaccines against malaria, tuberculosis (TB), influenza and dengue virus. The Challenge Grants program, established through the support of the United States Congress, will award $19 million to eight companies.
Since the announcement of the new grants puts malaria, TB, influenza and dengue in the news, this Vidyya spotlights something about each disease. Read a short history of Malaria, get the latest on exciting research for TB, print an easy refence chart comparing influenza to cold symptoms for your patients, or read a report published in August 2000 by the World Health Organization regarding the global strategies for the eradication of Dengue Hemorrhagic Fever.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.